Bo Zhang

Bo Zhang

Auto-generated profile, based on publicly available information

Bo Zhang

Key Laboratory of Sport Training of General Administration of Sport of China, International Joint Laboratory on High Performance Sports Research, Beijing Sport University, Beijing, China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2026 in BMC Sports Science, Medicine and Rehabilitation
Verified
Journal Article
Open access
PDF file
JLJian Li
Jian Li
RYRuolan Yang
Ruolan Yang
BZBo Zhang
Bo Zhang
THTianshuo Han
Tianshuo Han
JJJiashuang Jiang
Jiashuang Jiang
QHQi Han
Qi Han
Background: Remote ischemic preconditioning (RIPC) is a non-invasive intervention involving brief, repeated limb ischemia and is suggested to enhance muscle performance. However, findings in healthy men remain inconsistent, and few studies have examined upper-limb strength. This meta-analysis provides the first quantitative synthesis of acute RIPC effects on upper-body strength in healthy male adults, aiming to clarify its efficacy and practical relevance. Methods: English (PubMed, Web of Science, Embase, Cochrane Library) and Chinese (CNKI, Wanfang, VIP, CBM) databases were systematically searched up to March 16, 2025. Randomized crossover trials examining acute RIPC effects on upper-limb strength in healthy male adults were included. Primary outcomes involved maximal, explosive, and endurance strength measures. The review was registered with PROSPERO (CRD420251184757). Data were pooled using random-effects models, and heterogeneity was assessed via the I² statistic. Prespecified subgroup analyses examined moderators such as RIPC protocol (cycle number/duration) and strength outcome type (maximal, explosive, endurance). Results: Six randomized crossover trials involving 84 participants met inclusion criteria. The meta-analysis showed a small, positive, but non-significant overall effect of RIPC on upper-limb strength (SMD = 0.24, 95% CI: -0.02 to 0.51, p = 0.07) with low-to-moderate heterogeneity (I² = 32%). Subgroup analyses revealed no significant effects for maximal (SMD = 0.03, p = 0.85) or explosive strength (SMD = 0.13, p = 0.75). A moderate but non-significant improvement was observed for strength endurance (SMD = 0.54, 95% CI: -0.01 to 1.10, p = 0.054) with moderate heterogeneity (I² = 60%). Neither the number of ischemia–reperfusion cycles ( p = 0.40 for subgroup difference) nor the test time window (< 30 min vs. ≥ 30 min, p = 0.37) significantly moderated the effects. Conclusion: This first meta-analysis on RIPC and upper-limb strength suggests that acute RIPC does not reliably improve upper-body strength in healthy male adults. Despite a moderate effect size observed for strength endurance, the lack of statistical significance and the 95% confidence interval crossing zero indicate considerable uncertainty in this finding. Together with the limited and heterogeneous evidence, this indicates that current protocols do not consistently enhance strength performance. RIPC should therefore be regarded as a theoretically promising but practically unverified approach. Larger, well-controlled trials are needed to determine whether specific RIPC parameters or time windows can produce reproducible performance gains.